A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG after administration of Ketamine, Placebo and AZD6765 - AZD6765 EEG
Study identifier:D2285M00008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase I, Randomized, Double-Blind, Four-way Cross-over Study in Healthy Subjects to Assess Quantitative Electroencephalography (qEEG) parameters after the administration of ketamine, two doses of AZD6765 and Placebo
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6765, Ketamine, Placebo
Sex
Male
Actual Enrollment
36
Study type
Interventional
Age
30 Years - 45 Years
Date
Study Start Date: 01 May 2010
Primary Completion Date: 01 Jan 2011
Study Completion Date: 01 Jan 2011
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Oct 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD6765 75 mg | Drug: AZD6765 75 mg |
| Experimental: AZD6765 150 mg | Drug: AZD6765 150 mg |
| Active Comparator: Ketamine 0.5 mg/kg | Drug: Ketamine 0.5 mg/kg |
| Placebo Comparator: 125 mL sterile NaCl 0.9% | Drug: Placebo 125 mL sterile NaCl 0.9% |
Contacts
Investigators
Principal Investigator
Albena Patroneva
AstraZeneca
